Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by State of Alaska Department of Revenue

13 Apr 2026, 07:36 by Jessica Moore · The Cerbat Gem

State of Alaska Department of Revenue reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 4.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 18,303 shares of the biopharmaceutical company’s stock after selling 950 shares during the quarter. State of Alaska Department of Revenue’s holdings in Regeneron Pharmaceuticals were worth $14,127,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Board of the Pension Protection Fund purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $31,000. Salomon & Ludwin LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $27,000. FNY Investment Advisers LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $38,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $31,000. Finally, Caitlin John LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $34,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Jason Pitofsky sold 2,036 shares of the business’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the transaction, the senior vice president owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Huda Y. Zoghbi sold 1,638 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 3,774 shares of company stock valued at $2,942,738. 7.02% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $748.87 on Monday. The firm has a market cap of $79.17 billion, a price-to-earnings ratio of 18.02, a PEG ratio of 1.99 and a beta of 0.40. The stock has a 50 day moving average of $767.42 and a 200-day moving average of $721.06. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the previous year, the firm posted $12.07 EPS. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend was Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.05%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on REGN shares. JPMorgan Chase & Co. lifted their price objective on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Oppenheimer restated an “outperform” rating and set a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday, February 2nd. Royal Bank Of Canada lifted their price objective on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a “sector perform” rating in a report on Monday, March 2nd. Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $818.00 to $801.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Finally, Piper Sandler started coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 31st. They set an “overweight” rating and a $875.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $811.96.

Get Our Latest Stock Analysis on REGN

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Five stocks we like better than Regeneron Pharmaceuticals